6310
J. Zhao et al. / Bioorg. Med. Chem. 17 (2009) 6305–6310
Figure 6. Stereoviews of MFA model and the interaction points of 8k (a, high activity) and 8q (b, low activity).
Supplementary data
Table 5
Predicted and tested analgesic activities of 6e,p,q, 7c,f,r, and 8b,l,o
Supplementary data (Experimental procedures, biological eval-
uation methods, synthetic data, analytical data, physical chemical
constants, and spectral data) associated with this article can be
ꢀ
Compd
Pain threshold variation (X%)
Error
Error%
Tested value
Predicted value
6e
6p
6q
7c
7f
7r
8b
8l
39.4
28.36
51.9
36.36
50.00
22.00
50.97
22.75
39.76
37.683
32.757
42.976
39.11
43.775
18.314
45.617
20.809
42.748
ꢁ1.71
4.40
4.36
15.5
17.2
7.56
12.45
16.63
10.5
8.53
7.52
ꢁ8.92
References and notes
2.75
ꢁ6.25
ꢁ3.66
ꢁ5.35
ꢁ1.94
2.988
1. Li, X.; Bantel, C.; Conklin, D.; Childers, S. R.; Eisenach, J. C. Anesthesiology 2004,
100, 956.
2. Buvanendran, A.; Reuben, S. S.; Kroin, J. S. Tech. Region. Anesth. Pain Manage.
2007, 11, 19.
3. García-Martínez, C.; Fernández-Carvajal, A.; Valenzuela, B.; Gomis, A.; Nest, W.
V. D.; Ferroni, S.; Carreño, C.; Belmonte, C.; Ferrer-Montiel, A. J. Pain 2006, 7,
735.
8o
8b,l,o (Table 5). The correlations of predicting and measuring val-
ues are also shown in Figure 3. The results indicate that Eq. 1 ratio-
nally gives analgesic activities of 6e,p,q, 7c,f,r, and 8b,l,o, and the
errors range from 1.71 to 8.92. Most of the calculated activities
are close to the measured activities which means that Eq. 1 is prac-
tical to accurately predict analgesic activity of N-(2-chloro-9H-pur-
in-6-yl)-N-cyclopropylglycylamino acids and derivatives.
4. Guieua, R.; Peragut, J. C.; Roussel, P.; Hassani, H.; Sampieri, F.; Bechis, G.; Gola,
R.; Rochat, H. Pain 1996, 68, 271.
5. Schindler, M.; Harris, C. A.; Hayes, B.; Papotti, M.; Humphrey, P. P. A. Neurosci.
Lett. 2001, 297, 211.
6. Childers, S. R.; Li, X.; Xiao, R.; Eisenach, J. C. J. Neurochem. 2005, 93, 715.
7. Obata, H.; Li, X.; Eisenach, J. C. Anesthesiology 2004, 100, 1258.
8. Cappellacci, L.; Franchetti, P.; Vita, P.; Petrelli, R.; Lavecchia, A.; Costa, B.;
Spinetti, F.; Martini, C.; Klotz, K.; Grifantini, M. Bioorg. Med. Chem. 2008, 16, 336.
9. Calenbergh, S. V.; Link, A.; Fujikawa, S.; de Ligt, R. A. F.; Vanheusden, V.;
Golisade, A.; Blaton, N. M.; Rozenski, J.; IJzerman, A. P.; Herdewijn, P. J. Med.
Chem. 2002, 45, 1845.
10. Chang, L. C. W.; Küunzel, J. K.; Von, F. D.; Mulder-Krieger, T.; Spanjersberg, R. F.;
Roerink, S. F.; van den Hout, G.; Beukers, M. W.; Brussee, J.; Ijzerman, A. P. J.
Med. Chem. 2005, 48, 2045.
3. Conclusion
In conclusion, the conversions of N-[2-chloro-9-(tetrahydropy-
ran-2-yl)-9H-purin-6-yl]-N-cyclopropylglycylamino acid benzy-
lesters into N-(2-chloro-9H-purin-6-yl)-N-cyclopropylglycylamino
acid benzylesters and N-(2-chloro-9H-purin-6-yl)-N-cyclopropyl-
glycylamino acids led to obvious decrease in in vivo orally analge-
sic activity. This decrease in analgesic activity was mainly
characterized by both decreasing of analgesic potency and shorten-
ing of duration. Since the conversions did not alter the effective
time the decreasing of the analgesic potency and shortening of
the duration should be the result of the metabolism alteration.
The combination of proton probe with methyl group probe-based
3D QSAR analysis is able to give a satisfactory correlation for the
analgesic activity and the structure of N-(2-chloro-9H-purin-6-
yl)-N-cyclopropylglycylamino acids as well as derivatives, and
therefore is able to define the structural requirements for design-
ing a new analgesic of N-(2-chloro-9H-purin-6-yl)-N-cyclopropyl-
glycyl amino acid or derivatives.
11. Gregg, A.; Bottle, S. E.; Devine, S. M.; Figler, H.; Linden, J.; White, P.; Pouton, C.
W.; Urmaliya, V.; Scammells, P. J. Bioorg. Med. Chem. Lett. 2007, 17, 5437.
12. Ashton, T. D.; Baker, S. P.; Hutchinsonc, S. A.; Scammells, P. J. Bioorg. Med. Chem.
2008, 16, 1861.
13. Kehraus, S.; Gorzalka, S.; Hallmen, C.; Iqbal, J.; Müller, C. E.; Wright, A. D.;
Wiese, M.; König, G. M. J. Med. Chem. 2004, 47, 2243.
14. de Ligt, R. A. F.; van der Klein, P. A. M.; Künzel, J. K.; Von, F. D.; Lorenzen, A.; El
Maate, F. A.; Fujikawa, S.; van Westhoven, R.; van den Hoven, T.; Brussee, J.;
IJzerman, A. P. Bioorg. Med. Chem. 2004, 12, 139.
15. Chang, L. C. W.; Spanjersberg, R. F.; Künzel, J. K.; Von, F. D.; Mulder-Krieger, T.;
Brussee, J.; Ijzerman, A. P. J. Med. Chem. 2006, 49, 2861.
16. Maksay, G.; Nemes, P.; Vincze, Z.; Bíró, T. Bioorg. Med. Chem. 2008, 16, 2086.
17. Laube, B.; Maksay, G.; Schemm, R.; Betz, H. Trends Pharmacol. Sci. 2002, 23, 519.
18. Prusakiewicz, J. J.; Kingsley, P. J.; Kozak, K. R.; Marnett, L. J. Biochem. Biophys.
Res. Commun. 2002, 296, 612.
19. Yang, Z.; Aubrey, K. R.; Alroy, I.; Harvey, R. J.; Vandenberg, R. J.; Lynch, J. W.
Biochem. Pharmacol. 2008, 76, 1014.
20. Senokuchi, K.; Nakai, H.; Nagao, Y.; Sakai, Y.; Katsube, N.; Kawamura, M. Bioorg.
Med. Chem. 1998, 6, 441.
21. Karolak-Wojciechowska, J.; Mrozek, A.; Kiec´-Kononowicz, K. J. Mol. Struct.
2000, 516, 113.
22. Eulenburg, V.; Armsen, W.; Betz, H.; Gomeza, J. Trends Biochem. Sci. 2005, 30,
325.
Acknowledgments
23. Kang, G.; Zhao, M.; Zhang, X.; Peng, L.; Li, C.; Mao, M.; Ye, W.; Peng, S. Bioorg.
Med. Chem. Lett., 10106/j.bmcl.2009.05.077.
This work was completed in Beijing Area Major Laboratory of
Peptide and Small Molecular Drugs, and was supported by PHR
(IHLB, KZ200810025010), Special Project (2008ZX09401-002) of
China and the National Natural Science Foundation of China
(30672513).
24. Reiss, D.; Wichmann, J.; Tekeshima, H.; Kieffer, B. L.; Ouagazzal, A.-M. Eur. J.
Pharmacol. 2008, 579, 141.
25. Shaikh, A. R.; Ismael, M.; Carpio, C. A. D.; Tsuboi, H.; Koyama, M.; Endou, A.;
Kubo, M.; Broclawikc, E.; Miyamoto, A. Bioorg. Med. Chem. Lett. 2006, 16, 5917.
26. Doddareddy, M. R.; Cho, Y. S.; Koh, H. Y.; Pae, A. N. Bioorg. Med. Chem. 2004, 12,
3977.